Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Autor: Alieva AS; Almazov National Medical Research Centre, Saint Petersburg, Russia; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy. Electronic address: alieva_as@almazovcentre.ru., Olmastroni E; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy., Reutova OV; Almazov National Medical Research Centre, Saint Petersburg, Russia., Rotar OP; Almazov National Medical Research Centre, Saint Petersburg, Russia., Konradi AO; Almazov National Medical Research Centre, Saint Petersburg, Russia., Shlyakhto EV; Almazov National Medical Research Centre, Saint Petersburg, Russia., Baragetti A; Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy; SISA Centre, Bassini Hospital, Cinisello Balsamo, Milan, Italy., Grigore L; SISA Centre, Bassini Hospital, Cinisello Balsamo, Milan, Italy; IRCCS MultiMedica Hospital, Sesto S. Giovanni, Milan, Italy., Pellegatta F; SISA Centre, Bassini Hospital, Cinisello Balsamo, Milan, Italy; IRCCS MultiMedica Hospital, Sesto S. Giovanni, Milan, Italy., Casula M; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy; IRCCS MultiMedica Hospital, Sesto S. Giovanni, Milan, Italy., Tragni E; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy., Catapano AL; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy; IRCCS MultiMedica Hospital, Sesto S. Giovanni, Milan, Italy.
Jazyk: angličtina
Zdroj: Atherosclerosis. Supplements [Atheroscler Suppl] 2020 Dec; Vol. 42, pp. e41-e48.
DOI: 10.1016/j.atherosclerosissup.2021.01.008
Abstrakt: Background and Aim: The metabolic syndrome (MetS) has become one of the most important clinical issues in the cardiovascular field for this decade because of the marked increase in cardiovascular (CV) risk associated with a clustering of risk factors. The aim of the current study was to evaluate the relationship between MetS and its components and cardiovascular disease (CVD).
Methods: This population-based cross-sectional study was based on data from two studies carried out in Russia (ESSE-RF) and Italy (PLIC). One sample from each cohort was selected, matching individuals by sex and age. A comparison between samples of MetS components distribution and CV risk, according to SCORE chart, has been conducted.
Results: A total of 609 individuals (mean [SD] age 55 [8] years, about 39% males) for each cohort were selected. Almost half of PLIC cohort participants belonged to the moderate CV risk group (47% vs 27%), while in ESSE-RF cohort a relatively higher prevalence of individuals classified in the high and very high risk group was observed (19% vs 11%, 21% vs 6%, respectively). Overall, 43% of ESSE-RF participants were diagnosed with MetS, compared with the 27% of PLIC members (the difference in prevalence becomes 37% vs 21%, considering a more conservative cut-off for waist circumference). Both cohorts showed a trend towards the increase of MetS components moving from the lowest to the highest CV risk class, with a high prevalence of patients with four or five MetS determinants allocated in the high/very high CV risk group.
Conclusions: Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD, not only in subjects at high/very high CV risk, but also in those characterized by a lower risk, as even rare CV events that come from low risk group bring a tangible burden to healthcare systems.
Competing Interests: Declaration of competing interest All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. EO, AB, LG, FP, ET, MC, OVR report no disclosures. ALC reports grants from Amgen, Sanofi, Regeneron personal fees from Merck, Sanofi, Regeneron, AstraZeneca, Amgen, Novartis, outside the submitted work AA received research funding and/or honoraria for speaker bureau from Abbott, Amgen, KRKA, Pfizer, Recordati, Sanofi-Regeneron, Servier. OPR received research funding and/or honoraria for speaker bureau from KRKA, Pfizer, Recordati, Sanofi-Regeneron, Servier, Stada, Teva, Sandoz. AK received research funding and/or honoraria for speaker bureau from Servier, Novartis.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: